SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (OTCQB: NUMD), a medical device leader developing new nitric oxide delivery technology, announces that Dr. Brett Earl, Vice President of Medical Marketing for Nu-Med Plus, recently spoke with The Life Science Report where he discussed  the many uses of nitric oxide and Nu-Med Plus’s unique, low-cost delivery systems.

Dr. Brett Earl is Vice President of Medical Marketing for Nu-Med Plus and sits on its Board of Directors. He is a Board-Certified Emergency Physician with more than 15 years of experience in Emergency Medicine and more than a decade as a Functional Medicine Physician. He is currently the president and founder of Denali Medical Center. Dr. Earl received his medical degree from the University of Nevada- Reno. He has been published in numerous medical journals and serves on various medical boards in Utah

Jeff Robins CEO of Nu-Med Plus remarked, “Nu-Med Plus, Inc. (NUMD: OTCQB.MKTS) uses a completely different method from any of the previous processes. That's why it's been able to be patented and has implications for uses from the hospital setting to Third-World countries. The technology is sophisticated, safe, well-designed and portable. And finally, it just is much more cost effective as far as getting it into the hands of medical professionals and patients that need it.”

Inhaled nitric oxide is a medically essential gas that is currently used as a treatment for Neonate Hypoxia therapy (inadequate oxygen level in newborns), chronic obstructive pulmonary disease (COPD) and other pulmonary health issues. Precision doses of nitric oxide may have future applications for treating a variety of other diseases and complications that are currently being investigated. The Nu-Med Plus nitric oxide delivery products provide a portable, cost-effective, efficient, and user-friendly method of delivering precise therapeutic doses of nitric oxide to patients.

Media Contact: eric@s2spr.com

About Nu-Med Plus, Inc.: Nu-Med Plus, Inc. founded in 2011, is a medical device development company created to explore medical applications of newly developed nitric oxide technologies. The strategy focuses on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use. For more information please visit www.nu-medplus.com. Follow Nu-Med Plus on Twitter and LinkedIn for the latest news.

Forward-Looking Statements: Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.